Pharmaceuticals US

US PD-1 and PD-L1 Inhibitors Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

US PD-1 and PD-L1 Inhibitors Market Industry Trends and Forecast to 2034: Segmented by (Drug, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $23.05 Bn Placeholder estimate
Estimate 2025 $24.71 Bn 41.6% of the global market
Projected 2034 $46.20 Bn 87% Adds $21.49 Bn over 9 forecast years
CAGR 2025–2034 7.2% Faster than 58% of 180 Pharmaceuticals markets here
Key players 6 +1
  • US is 41.6% of the global market.
  • In North America, the largest is US (this report) at $24.71 Bn.
  • Fastest growing: Canada at 8.8% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$21.49 Bn total, 2026–2034

Year-by-year market size, 2024–2034
PD-1 and PD-L1 Inhibitors Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $23.05 Bn — —
2025 (base) $24.71 Bn +$1.66 Bn —
2026 (forecast) $26.49 Bn +$1.78 Bn +7.2%
2027 (forecast) $28.40 Bn +$1.91 Bn +14.9%
2028 (forecast) $30.44 Bn +$2.04 Bn +23.2%
2029 (forecast) $32.64 Bn +$2.19 Bn +32.1%
2030 (forecast) $34.99 Bn +$2.35 Bn +41.6%
2031 (forecast) $37.50 Bn +$2.52 Bn +51.8%
2032 (forecast) $40.20 Bn +$2.70 Bn +62.7%
2033 (forecast) $43.10 Bn +$2.89 Bn +74.4%
2034 (forecast) $46.20 Bn +$3.10 Bn +87%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

US PD-1 and PD-L1 Inhibitors Market Analysis at a glance
Market size, 2025$24.71 Bn placeholder estimate
Forecast, 2034$46.20 Bn placeholder estimate
Growth (CAGR), 2025–20347.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, indication and end user (see all)
Key playersMerck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, BeiGene and 1 more (see all)
Regulator in the USFDASource: US Food and Drug Administration. Checked 14 Nov 2026.
Active clinical trials356 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The US PD-1 and PD-L1 Inhibitors Market Analysis Executive Summary

PD-1 and PD-L1 inhibitors are checkpoint drugs that release the brakes on the immune system so it can attack cancer.

Key segments of the PD-1 and PD-L1 Inhibitors market include drug (Pembrolizumab, Nivolumab and Atezolizumab) and indication (Lung Cancer, Melanoma and Kidney Cancer).

Bar chart: US PD-1 and PD-L1 Inhibitors market size, 2024–2034, placeholder estimates. $23.05 Bn in 2024, $24.71 Bn in 2025 and $46.20 Bn in 2034, 7.2% CAGR.
US PD-1 and PD-L1 Inhibitors market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

US PD-1 and PD-L1 Inhibitors Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the PD-1 and PD-L1 Inhibitors market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the PD-1 and PD-L1 Inhibitors market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the PD-1 and PD-L1 Inhibitors market, especially in low- and middle-income countries.

Competitive Landscape for PD-1 and PD-L1 Inhibitors Market in US

The PD-1 and PD-L1 Inhibitors market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for PD-1 and PD-L1 Inhibitors Market in US

PD-1 and PD-L1 Inhibitors in the US: rules, payment and research

New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.⁠[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).⁠[2] ClinicalTrials.gov lists 356 studies on PD-1 and PD-L1 Inhibitors that are recruiting, active or about to start in the US.⁠[3]

[1] US Food and Drug Administration. Checked 14 Nov 2026.

[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for PD-1 and PD-L1 Inhibitors. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in PD-1 and PD-L1 Inhibitors right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

PD-1 and PD-L1 Inhibitors in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 19 Nov 2026.

Free data on this topic

Inside the US

Quick answers

Frequently asked questions

How big is the PD-1 and PD-L1 Inhibitors market in the US?
Placeholder estimate: about $24.71 Bn in 2025, rising to about $46.20 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the PD-1 and PD-L1 Inhibitors market in the US growing?
Placeholder estimate: about 7.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the PD-1 and PD-L1 Inhibitors market report cover?
The report splits the market by drug (Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab and more), indication (Lung Cancer, Melanoma, Kidney Cancer, Other Solid Tumors) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the PD-1 and PD-L1 Inhibitors market?
Key players include Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, BeiGene and Innovent Biologics.
What is driving the PD-1 and PD-L1 Inhibitors market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the PD-1 and PD-L1 Inhibitors market. Faster approvals and new combinations are improving survival.
Who regulates PD-1 and PD-L1 Inhibitors in the US?
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead. Source: US Food and Drug Administration. Checked 14 Nov 2026.
How is healthcare paid for in the US?
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS). Source: Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
How many clinical trials on PD-1 and PD-L1 Inhibitors are running in the US?
356 studies are recruiting, active or about to start in the US, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
How much research is published on PD-1 and PD-L1 Inhibitors?
PubMed lists 1,230 papers on PD-1 and PD-L1 Inhibitors added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in US

See all

Related on oncology

See the topic